Better Health for All

CareDx's core business is 100% focused on diagnostic solutions for transplant patients, with products like AlloSure and AlloMap designed to detect organ rejection earlier and improve patient management.

AlloSure Kidney has shown a median 3-month increase in detection time and is used by 70% of US kidney transplant hospitals, with over 100,000 patients tested since 2017. AlloMap Kidney has a 95% negative predictive value for allograft rejection. The company has invested hundreds of millions of dollars over two decades in transplant care, demonstrating a strong commitment to health innovation. CareDx's products, by detecting potential issues earlier, serve as preventative health measures. The company also provides information on AlloSure score zones and their implications, contributing to health education.

Fair Pay & Worker Respect

The CEO's average annual salary is $1,050,437

, while the median estimated annual employee salary is $145,734 , resulting in a CEO to median employee pay ratio of approximately 7.21:1. Employee reviews on Glassdoor indicate an overall rating of 3.1 out of 5 stars , and on Indeed, 3.6 out of 5 stars. 50% of employees would recommend working at the company to a friend. Employee reviews mention high turnover within security roles , and one review indicates an annual turnover rate of 50-60%. The company states it offers a comprehensive benefits package including health insurance , and 75-80% of employees are covered by employer-funded health plans.

Honest & Fair Business

CareDx's Board of Directors has 9 out of 10 members identified as independent, indicating 90% conflict-free status.

The company's Code of Business Conduct and Ethics includes protection for persons reporting violations, and the Audit and Finance Committee oversees procedures for confidential, anonymous employee comments on accounting or auditing matters. However, there is no evidence of independent investigation processes for these reports. The company corrected certain misstatements in its comparative financial statements for the three and nine months ended September 30, 2024, which it determined were not material. The company achieved SOC 2 Type 2 Audit Compliance for data security capabilities, and its 2023 Carbon Footprint was verified by the Center for Sustainability and Excellence (CSE). The Corporate Governance Guidelines and Code of Business Conduct and Ethics apply to all employees, officers, and directors, including executive and senior financial officers, and an anti-corruption policy exists, but specific details on training frequency or effectiveness metrics are not provided.

Kind to Animals

No evidence was found in the provided articles to assess CareDx, Inc. against any of the 'Kind to Animals' KPIs. The articles primarily discuss a partnership where CareDx provides a cell-free DNA testing solution for pre-clinical animal models and human clinical studies of bioengineered organs developed by Miromatrix.

This information does not provide specific data points regarding CareDx's own cruelty-free certifications, animal testing policies or volumes, use of alternative testing methods for its own products, ethical sourcing, or any other animal welfare metrics relevant to the rubric.

Planet-Friendly Business

CareDx reported zero environmental compliance violations in 2024.

The company also stated that some of its facilities hold LEED and equivalent energy efficiency certifications, but did not provide a specific percentage of certified buildings.

Respect for Cultures & Communities

The provided articles do not contain specific quantitative data or concrete facts related to any of the KPIs for 'Respect for Cultures & Communities'.

The articles discuss general ESG strategies, corporate compliance, and social responsibility initiatives like health equity and patient advocacy, but they explicitly state a lack of specific metrics on community engagement, cultural preservation, local employment, or grievance mechanisms.

Safe & Smart Tech

CareDx experienced a data breach in February 2024, confirmed by May 2024, which affected at least 270,512 individuals, including PII and PHI.

The company filed three HIPAA breach reports with the HHS Office for Civil Rights and offered 24 months of credit monitoring and identity theft remediation services to affected individuals. Systems and security protocols were reinforced post-breach. CareDx holds Soc2 Type 2 security certification. The company's privacy policy allows users to update/correct information, unsubscribe from marketing, and exercise state-specific privacy rights, but does not detail comprehensive control over personal data or privacy settings. CareDx mentions compliance with HIPAA and state-specific privacy laws, but the breach and subsequent HIPAA reports indicate gaps in compliance. The company conducts vulnerability assessments and uses cybersecurity threat intelligence.

Zero Waste & Sustainable Products

The provided articles do not contain specific quantitative data or detailed qualitative information for any of the KPIs under the 'Zero Waste & Sustainable Products' value. While recycling programs and efforts to reduce consumable plastics, energy consumption, and water usage are mentioned, no specific metrics, percentages, or outcomes are provided to assess their effectiveness or align with the rubric's quantitative thresholds.

Consequently, there is insufficient evidence to score any of the KPIs.